NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer

Phase 2 Active not recruiting 43 enrolled Chinese University of Hong Kong

NaSingle-groupOpen-labelTreatment

Summary

This is an open label, single arm, non-randomized, multi-site, phase 2 clinical trial of neoadjuvant pembrolizumab in combination with gemcitabine-cisplatin for 2 cycles,followed by concurrent pembrolizumab-cisplain-radiation, and then maintainence pembrolizumab monotherpy given every 3 weeks for a total treatment duration of 12 months, in previously untreated stage IVA ( UICC 8 th Edition ) nasopharyngeal cancer(NPC).

Timeline

Start: 2019-05-03
Primary completion: 2025-01-25
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pembrolizumab	Monoclonal antibody	200 mg	—

Indications

No indication recorded.